Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis.
Murali M Chakinala, Daniel W Coyne, Raymond L Benza...
https://pubmed.ncbi.nlm.nih.gov/29174533/Actively Recruiting
Led by University of Giessen · Updated on 2026-09-08
400
Participants Needed
2
Research Sites
8 weeks
Total Duration
This research aims to explore how urinary and plasma biomarkers relate to changes in kidney function, specifically estimated glomerular filtration rate eGFR, in patients with pulmonary hypertension PH. PH is a serious and progressive condition linked to right heart dysfunction, heart failure, and increased risk of death. Kidney disease affects about 35% of PH patients and is associated with worse outcomes, potentially due to heart-related changes impacting the kidneys. The study observes two groups patients diagnosed with PH confirmed by right heart catheterization, with or without PH-specific treatment, and patients in whom PH was ruled out by the same test. No interventions or treatments are administered as part of this study. Instead, the focus is on collecting data and analyzing biomarkers related to kidney function and heart health over time. Participants will undergo right heart catheterization and will be followed for 12 months to monitor major adverse kidney events and worsening pulmonary hypertension or heart failure. Researchers will also track all-cause mortality, kidney function decline, and deaths related to pulmonary hypertension. No treatment is provided, but participants will be monitored through regular assessments and follow-up visits to help understand the connection between heart and kidney health in PH.
CONDITIONS
Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension
F
Faeq Husain-Syed, MD
B
Birgit Jennert, MLA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Giessen
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants will be observed and followed for 12 months with assessments of kidney function and heart health without receiving any study treatment.
Regular follow-up visits during the year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Murali M Chakinala, Daniel W Coyne, Raymond L Benza...
https://pubmed.ncbi.nlm.nih.gov/29174533/Faeq Husain-Syed, Matthew F DiFrancesco, Rajat Deo...
https://pubmed.ncbi.nlm.nih.gov/37664568/University of Giessen
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Collaborating Sponsor